The American healthcare system has long prioritized managing disease over preventing it. That’s not a critique — it’s a business model. Chronic illness has been engineered into profitability, with incentives aligned to recurring prescriptions, not lasting cures.
That model just met serious resistance. For the first time, industry leadership appears to be entertaining reforms that would reduce profits in favor of better outcomes. Not out of charity, but because the pressure to change is now greater than the risk of standing still. Drug pricing, efficacy testing, and trust have all reached a breaking point — and the companies that once thrived on the old system are beginning to turn toward something radically different.
This is not a soft pivot. It’s a reversal of incentives, a reorientation of power, and a possible inflection point in how Americans experience healthcare. If this holds, the era of profiting from sickness may finally be cracking.